Boulevard Bio
PrivateLast Round
Launch Financing
Aug 12, 2026
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Boulevard Bio is a biotechnology company that develops multi-specific antibodies for the treatment of B cell-driven autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Boulevard Bio Comparables
Compare Boulevard Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oblenio Bio | 88% | |
| Kali Therapeutics | 88% | |
| UCB | 79% | |
Boulevard Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Launch Financing | Aug 12, 2026 |
Boulevard Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Launch Financing |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2026
$65M raised with Deerfield Management leading.
Boulevard Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Boulevard Bio's valuation, stock price, and market status.